Update on European melphalan shortages |
Update on European melphalan shortages
Myeloma Patients Europe (MPE), a network of over 40 organisations representing patients with myeloma, is exploring issues with shortages of melphalan – a drug routinely used to treat myeloma. There have been ongoing issues accessing melphalan in European countries, namely due to problems in the supply chain.
Whilst we have been informed that the supply chain issues are now resolved, we have continuing concerns that there may be other factors impacting on the availability of melphalan in European countries.
To provide information on access to melphalan where you live, please complete the following short survey. We anticipate it will take no longer than 5 minutes of your time to complete. If you have any questions about the survey or would prefer to discuss your answers over the phone, please email MPE Policy and Public Affairs Manager Kate Morgan at morgan@mpeurope.org
Whilst we have been informed that the supply chain issues are now resolved, we have continuing concerns that there may be other factors impacting on the availability of melphalan in European countries.
To provide information on access to melphalan where you live, please complete the following short survey. We anticipate it will take no longer than 5 minutes of your time to complete. If you have any questions about the survey or would prefer to discuss your answers over the phone, please email MPE Policy and Public Affairs Manager Kate Morgan at morgan@mpeurope.org